Patrick D McGorry1, Barnaby Nelson1, Connie Markulev1, Hok Pan Yuen1, Miriam R Schäfer2, Nilufar Mossaheb3, Monika Schlögelhofer3, Stephan Smesny4, Ian B Hickie5, Gregor Emanuel Berger6, Eric Y H Chen7, Lieuwe de Haan8, Dorien H Nieman8, Merete Nordentoft9, Anita Riecher-Rössler10, Swapna Verma11, Andrew Thompson12, Alison Ruth Yung13, G Paul Amminger14. 1. Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia2Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia. 2. Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia3Department of Psychiatry, Medical University of Vienna, Vienna, Austria. 3. Department of Psychiatry, Medical University of Vienna, Vienna, Austria. 4. Department of Psychiatry, University Hospital, Jena, Germany. 5. Brain and Mind Research Institute, University of Sydney, Sydney, Australia. 6. Child and Adolescent Psychiatric Service of the Canton of Zurich, Zurich, Switzerland. 7. Department of Psychiatry, University of Hong Kong, Hong Kong. 8. Department of Psychiatry, Academic Medical Center, Amsterdam, the Netherlands. 9. Psychiatric Centre Bispebjerg, Copenhagen, Denmark. 10. Psychiatric University Clinics Basel, Basel, Switzerland. 11. Institute of Mental Health, Singapore, Singapore. 12. Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia12Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, England13North Warwickshire Early Intervention in Psychosis Service, Coventry and Warwickshire National Health Service Partnership Trust, Coventry, England. 13. Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia14Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, England15Greater Manchester West National Health Service Mental Health Foundation Trust, Manchester, England. 14. Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia2Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia3Department of Psychiatry, Medical University of Vienna, Vienna, Austria.
Abstract
IMPORTANCE: A promising treatment to prevent onset and improve outcomes in patients at ultrahigh risk for psychosis is dietary supplementation with long-chain ω-3 polyunsaturated fatty acids (PUFAs). OBJECTIVE: To determine whether treatment with ω-3 PUFAs in combination with a high-quality psychosocial intervention (cognitive behavioral case management [CBCM]) is more effective than placebo plus CBCM. DESIGN, SETTING, AND PARTICIPANTS: NEURAPRO, a double-blind, placebo-controlled, randomized clinical trial, was conducted from March 1, 2010, to September 30, 2014, in 10 specialized early psychosis treatment services in Australia, Asia, and Europe. The primary analysis used the intention-to-treat approach. INTERVENTIONS: A daily dose of 1.4 g of ω-3 PUFAs or placebo (paraffin oil), plus 20 or fewer sessions of CBCM over the 6-month study period. MAIN OUTCOMES AND MEASURES: The primary outcome was transition to psychosis status at 6 months. The secondary outcomes were general levels of psychopathology and functioning, as assessed by the Brief Psychiatric Rating Scale (BPRS) (range, 24-168), Scale for the Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-Åsberg Depression Rating Scale (MADRS) (range, 0-60), Young Mania Rating Scale (YMRS) (range, 0-44), Social and Occupational Functioning Assessment Scale (SOFAS) (range, 0-100), and the Global Functioning: Social and Role scale (range, 0-10). For SOFAS and Global Functioning: Social and Role scale, higher scores were better; for other measures, lower scores were better. RESULTS: In this study of 304 adults at ultrahigh risk for psychotic disorders, 153 (50.3%) received ω-3 PUFAs and 151 (49.7%) received placebo. In all, 139 (45.7%) were male; mean (SD) age was 19.1 (4.6) years. The Kaplan-Meier-estimated 6-month transition rates were 5.1% (95% CI, 1.3%-8.7%) in the control group and 6.7% (95% CI, 2.3%-10.8%) in the ω-3 PUFA group. At 12 months, the rates were 11.2% (95% CI, 5.5%-16.7%) in the control group and 11.5% (95% CI, 5.8%-16.9%) in the ω-3 PUFA group. No significant difference was observed between the transition rates of both groups (hazard ratio, 1.1; 95% CI, 0.55-2.23; P = .76, stratified log-rank test). CONCLUSIONS AND RELEVANCE: This trial clearly failed to replicate the findings of the original single-center trial. The most likely explanation is that ω-3 PUFAs lack efficacy under these conditions. However, the lower-than-expected transition rate may have prevented a test of the main hypothesis. Given the substantial symptomatic and functional improvement in both groups, the other treatments received (ie, CBCM and antidepressants) likely produced a ceiling effect beyond which ω-3 PUFAs, even if effective, could not be shown to confer additional benefits. Nevertheless, the main conclusion is that ω-3 PUFAs are not effective under conditions where good quality, evidence-based psychosocial treatment is available. TRIAL REGISTRATION: anzctr.org.au Identifier: 12608000475347.
IMPORTANCE: A promising treatment to prevent onset and improve outcomes in patients at ultrahigh risk for psychosis is dietary supplementation with long-chain ω-3 polyunsaturated fatty acids (PUFAs). OBJECTIVE: To determine whether treatment with ω-3 PUFAs in combination with a high-quality psychosocial intervention (cognitive behavioral case management [CBCM]) is more effective than placebo plus CBCM. DESIGN, SETTING, AND PARTICIPANTS: NEURAPRO, a double-blind, placebo-controlled, randomized clinical trial, was conducted from March 1, 2010, to September 30, 2014, in 10 specialized early psychosis treatment services in Australia, Asia, and Europe. The primary analysis used the intention-to-treat approach. INTERVENTIONS: A daily dose of 1.4 g of ω-3 PUFAs or placebo (paraffin oil), plus 20 or fewer sessions of CBCM over the 6-month study period. MAIN OUTCOMES AND MEASURES: The primary outcome was transition to psychosis status at 6 months. The secondary outcomes were general levels of psychopathology and functioning, as assessed by the Brief Psychiatric Rating Scale (BPRS) (range, 24-168), Scale for the Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-Åsberg Depression Rating Scale (MADRS) (range, 0-60), Young Mania Rating Scale (YMRS) (range, 0-44), Social and Occupational Functioning Assessment Scale (SOFAS) (range, 0-100), and the Global Functioning: Social and Role scale (range, 0-10). For SOFAS and Global Functioning: Social and Role scale, higher scores were better; for other measures, lower scores were better. RESULTS: In this study of 304 adults at ultrahigh risk for psychotic disorders, 153 (50.3%) received ω-3 PUFAs and 151 (49.7%) received placebo. In all, 139 (45.7%) were male; mean (SD) age was 19.1 (4.6) years. The Kaplan-Meier-estimated 6-month transition rates were 5.1% (95% CI, 1.3%-8.7%) in the control group and 6.7% (95% CI, 2.3%-10.8%) in the ω-3 PUFA group. At 12 months, the rates were 11.2% (95% CI, 5.5%-16.7%) in the control group and 11.5% (95% CI, 5.8%-16.9%) in the ω-3 PUFA group. No significant difference was observed between the transition rates of both groups (hazard ratio, 1.1; 95% CI, 0.55-2.23; P = .76, stratified log-rank test). CONCLUSIONS AND RELEVANCE: This trial clearly failed to replicate the findings of the original single-center trial. The most likely explanation is that ω-3 PUFAs lack efficacy under these conditions. However, the lower-than-expected transition rate may have prevented a test of the main hypothesis. Given the substantial symptomatic and functional improvement in both groups, the other treatments received (ie, CBCM and antidepressants) likely produced a ceiling effect beyond which ω-3 PUFAs, even if effective, could not be shown to confer additional benefits. Nevertheless, the main conclusion is that ω-3 PUFAs are not effective under conditions where good quality, evidence-based psychosocial treatment is available. TRIAL REGISTRATION: anzctr.org.au Identifier: 12608000475347.
Authors: Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry Journal: Early Interv Psychiatry Date: 2017-07-18 Impact factor: 2.732
Authors: Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli Journal: World Psychiatry Date: 2018-06 Impact factor: 49.548
Authors: Adam J Ciarleglio; Gary Brucato; Michael D Masucci; Rebecca Altschuler; Tiziano Colibazzi; Cheryl M Corcoran; Francesca M Crump; Guillermo Horga; Eugénie Lehembre-Shiah; Wei Leong; Scott A Schobel; Melanie M Wall; Lawrence H Yang; Jeffrey A Lieberman; Ragy R Girgis Journal: Psychol Med Date: 2018-06-28 Impact factor: 7.723
Authors: Anna R Docherty; Eduardo Fonseca-Pedrero; Martin Debbané; Raymond C K Chan; Richard J Linscott; Katherine G Jonas; David C Cicero; Melissa J Green; Leonard J Simms; Oliver Mason; David Watson; Ulrich Ettinger; Monika Waszczuk; Alexander Rapp; Phillip Grant; Roman Kotov; Colin G DeYoung; Camilo J Ruggero; Nicolas R Eaton; Robert F Krueger; Christopher Patrick; Christopher Hopwood; F Anthony O'Neill; David H Zald; Christopher C Conway; Daniel E Adkins; Irwin D Waldman; Jim van Os; Patrick F Sullivan; John S Anderson; Andrey A Shabalin; Scott R Sponheim; Stephan F Taylor; Rachel G Grazioplene; Silviu A Bacanu; Tim B Bigdeli; Corinna Haenschel; Dolores Malaspina; Diane C Gooding; Kristin Nicodemus; Frauke Schultze-Lutter; Neus Barrantes-Vidal; Christine Mohr; William T Carpenter; Alex S Cohen Journal: Schizophr Bull Date: 2018-10-15 Impact factor: 9.306
Authors: Frank Iorfino; Elizabeth M Scott; Joanne S Carpenter; Shane P Cross; Daniel F Hermens; Madhura Killedar; Alissa Nichles; Natalia Zmicerevska; Django White; Adam J Guastella; Jan Scott; Patrick D McGorry; Ian B Hickie Journal: JAMA Psychiatry Date: 2019-11-01 Impact factor: 21.596
Authors: Michael Berk; Robert Post; Aswin Ratheesh; Emma Gliddon; Ajeet Singh; Eduard Vieta; Andre F Carvalho; Melanie M Ashton; Lesley Berk; Susan M Cotton; Patrick D McGorry; Brisa S Fernandes; Lakshmi N Yatham; Seetal Dodd Journal: World Psychiatry Date: 2017-10 Impact factor: 49.548